NCT06162221Phase 1, phase 2Recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Study sponsor: Revolution Medicines, Inc. · RVMD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06Estimated
Enrollment · participants616Estimated
Source updated2026-10-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.